XERS Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -1.86%, SMA50 -0.42%, SMA200 7.85%). The stock’s 14-day RSI is 47.82 (neutral), while the ATR of 0.33 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -28.37% below its high and over 109.58% above its low. Average 10-day trading volume of 1.26 million shares is below the 3-month average of 2.06 million, indicating normal recent market interest.

Xeris Biopharma Holdings, Inc. has 161.48 million shares outstanding. The public float is 154.25 million shares, elevated short interest at 9.48% of float. This equals 14.71 million shares. The short ratio is 4.52 days. Institutional investors hold 61.94% of the float. Insiders own 3.87%. Redmile Group, LLC holds 3.00 million shares, Shannon John Patrick Jr has 2.71 million shares and Edick Paul R has 2.29 million shares. Over the past six months, insider transactions show net selling. They sold 487.95 thousand shares across 13 transactions.

Xeris Biopharma Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

Xeris Biopharma Holdings, Inc. generated EPS of -$0.10 over the past year. Five-year average earnings growth is 40.01%. The latest quarter delivered EPS of $0.00. The next quarter is forecast at $0.02. Next year's EPS is expected at $37.34. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 5 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $4.00. The high target offers 149.31% upside. The low target suggests -44.6% downside. The mean target is $9.71. This offers 34.49% upside. Xeris Biopharma Holdings, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by -65.0%. The prior quarter beat by -66.67%. Over the last six quarters, Apple has recorded several small beats. These include -9.09% in August 08, 2024.

Our AI price prediction model suggests that Xeris Biopharma Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.4%, with price expected at $6.83 by February 24, 2026, within a range of $6.54 to $7.13 3-Month Outlook: Projected rise of 4.02%, reaching $7.51 by May 08, 2026, with a range of $7.27 to $7.76. 1-Year Outlook: Projected gain of 233.52%, with price at $24.08 by February 10, 2027, within a range of $23.65 to $30.53.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares are flat -3.06% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Xeris Biopharma Holdings, Inc. trading at a premium to the broader market with a P/E of -81.09. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.58, suggesting 18.84% upside. Our AI forecast model points to short-term weakness (-5.4% over two weeks), a medium-term rise (4.02% over three months), and a longer-term gain (233.52% over one year), with expected trading ranges indicating moderate volatility.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) closed at $7.22 USD, gaining $0.26 (3.74%) from the previous close of $6.96. The stock is currently mid-range between its 52-week high and low $3.48 and $10.08. With a market capitalization of about $1.20 billion, Xeris Biopharma Holdings, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.93). Key stats such as the average daily volume over the past year has been around 2.07 million shares, volume is running light vs its 52-week average. Headquartered in Chicago, IL, Xeris Biopharma Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John Shannon, the company employs approximately 394 people and listed since June 21, 2018. Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.

Xeris Biopharma Holdings, Inc. trades at a P/E ratio of -81.09, slightly below the S&P 500 average, with a price-to-sales ratio of 4.45 and a price-to-book ratio of -1472.92 indicating negative book value, which may reflect financial stress. The P/FCF stands at 59.76, also above market averages.